Dexmedetomidine preconditioning ameliorates kidney ischemia-reperfusion injury

Pharmacology Research and Perspectives

Volumn 2, Issue 3, 2014, Pages

  Lempiäinen, Juha ^a   Finckenberg, Piet ^a   Mervaala, Elina E ^a   Storvik, Markus ^b   Kaivola, Juha ^c   Lindstedt, Ken ^c   Levijoki, Jouko ^c   Mervaala, Eero M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

Acute kidney injury; AHR; CD44; dexmedetomidine; fadolmidine; ischemia reperfusion injury; NRF2; p38; Rac

Indexed keywords

ADENYLATE KINASE; AROMATIC HYDROCARBON RECEPTOR; CREATININE; DEXMEDETOMIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FADOLMIDINE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SIRTUIN 1; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF1;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL NEPHRITIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART RATE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; ISCHEMIC PRECONDITIONING; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE NECROSIS; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TISSUE MICROARRAY; TRANSCRIPTOMICS; UPREGULATION; WESTERN BLOTTING;

EID: 84937840515     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.45     Document Type: Article

References (45)

1. Barzilai N, Bartke A (2009). Biological approaches to mechanistically understand the healthy life span extension achieved by calorie restriction and modulation of hormones. J Gerontol A Biol Sci Med Sci 64: 187–191.
2. Bonventre JV (2002). Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 11: 43–48.
3. Chase SD, Magnani JL, Simon SI (2012). E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. Ann Biomed Eng 40: 849–859.
4. Coursin DB, Coursin DB, Maccioli GA (2001). Dexmedetomidine. Curr Opin Crit Care 7: 221–226.
5. Cussac D, Schaak S, Gales C, Flordellis C, Denis C, Paris H (2002). alpha(2B)-Adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells. Am J Physiol Renal Physiol 282: 943–952.
6. Dahmani S, Rouelle D, Gressens P, Mantz J (2010). Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation. Anesthesiology 112: 373–383.
7. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. (2003). DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4: 3.
8. Devarajan P. (2006). Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17:1503–1520.
9. Forbes JM, Hewitson TD, Becker GJ, Jones CL (2000). Ischemic acute renal failure: Long-term histology of cell and matrix changes in the rat. Kidney Int 57: 2375–2385.
10. Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR, Sladen RN (2006). Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth 18: 422–426.
11. Fujii T, Kurata H, Takaoka M, Muraoka T, Fujisawa Y, Shokoji T, et al. (2003). The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. Eur J Pharmacol 481: 241–248.
12. Gu J, Chen J, Xia P, Tao G, Zhao H, Ma D (2011a). Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice. Acta Anaesthesiol Scand 55: 1272–1278.
13. Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, et al. (2011b). Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care 15: 153.
14. Hamasaki J, Tsuneyoshi I, Katai R, Hidaka T, Boyle WA, Kanmura Y (2002). Dual alpha(2)-adrenergic agonist and alpha(1)-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries. Anesth Analg 94: 1434–1440.
15. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, et al. (2010). Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem 285: 13045–13056.
16. Ibacache M, Sanchez G, Pedrozo Z, Galvez F, Humeres C, Echevarria G, et al. (2012). Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart. Biochim Biophys Acta 1822: 537–545.
17. Jolkkonen J, Puurunen K, Koistinaho J, Kauppinen R, Haapalinna A, Nieminen L, et al. (1999). Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 372: 31–36.
18. Kaur M, Singh PM. (2011). Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays and Res 5: 128–133.
19. Kilic K, Hanci V, Selek S, Sozmen M, Kilic N, Citil M, et al. (2012). The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits. J Surg Res 178: 223–232.
20. Kuhmonen J, Pokorny J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen PS, et al. (1997). Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 87: 371–377.
21. Kulka PJ, Tryba M, Zenz M (1996). Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 24: 947–952.
22. Kunzendorf U, Haase M, Rolver L, Haase-Fielitz A (2010). Novel aspects of pharmacological therapies for acute renal failure. Drugs 70: 1099–1114.
23. Lehtimaki J, Leino T, Koivisto A, Viitamaa T, Lehtimaki T, Haapalinna A, et al. (2008). In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action. Eur J Pharmacol 599: 65–71.
24. Leino T, Viitamaa T, Haapalinna A, Lehtimaki J, Virtanen R (2009). Pharmacological profile of intrathecal fadolmidine, a alpha2-adrenoceptor agonist, in rodent models. Naunyn Schmiedebergs Arch Pharmacol 380: 539–550.
25. Lempiäinen J, Finckenberg P, Levijoki J, Mervaala E (2012). AMPK activator AICAR ameliorates ischemia reperfusion injury in the rat kidney. Br J Pharmacol 166: 1905–1915.
26. Lempiäinen J, Finckenberg P, Mervaala E, Sankari S, Levijoki J, Mervaala E (2013). Caloric restriction ameliorates kidney ischemia reperfusion injury through PGC-1alpha-eNOS-pathway and enhanced autophagy. Acta Physiol (Oxf) 208: 410–421.
27. Linkermann A, Bräsen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U, et al. (2012). Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 81: 751–761.
28. Linkermann A, Heller JO, Prókai A, Weinberg JM, De Zen F, Himmerkus N, et al. (2013). The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol 24: 1545–1557.
29. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, et al. (2004). Dexmedetomidine produces its neuroprotective effect via the alpha 2A.adrenoceptor subtype. Eur J Pharmacol 502: 87–97.
30. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M (1993). Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 79: 306–312.
31. Mantz J, Josserand J, Hamada S (2011). Dexmedetomidine: new insights. Eur J Anaesthesiol 28: 3–6.
32. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM (2000). The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol 95: 472–478.
33. Nakano A, Cohen MV, Critz S, Downey JM (2000). SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 95: 466–471.
34. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, et al. (2001). Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 281: 948–957.
35. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, et al. (2006). Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26: 9220–9231.
36. Richa F, Yazigi A, El Hage C, Jebara S, Hokayem N, Antakly MC (2004). Demedetomidine: an agent for controlled hypotension in maxillo-facial surgery. Eur J Anaesthesiol 21: 60.
37. Schmitz JM, Graham RM, Sagalowsky A, Pettinger WA (1981). Renal alpha-1 and alpha-2 adrenergic receptors: biochemical and pharmacological correlations. J Pharmacol Exp Ther 219: 400–406.
38. Sharfuddin AA, Molitoris BA (2011). Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 7: 189–200.
39. Si Y, Bao H, Han L, Shi H, Zhang Y, Xu L, et al. (2013). Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med 11: 141.
40. Spurgeon KR, Donohoe DL, Basile DP (2005). Transforming growth factor-beta in acute renal failure: receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury. Am J Physiol Renal Physiol 288: 568–577.
41. Tang G, Yue Z, Talloczy Z, Hagemann T, Cho W, Messing A, et al. (2008). Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Hum Mol Genet 17: 1540–1555.
42. Taoda M, Adachi YU, Uchihashi Y, Watanabe K, Satoh T, Vizi ES (2001). Effect of dexmedetomidine on the release of [3H]-noradrenaline from rat kidney cortex slices: characterization of alpha2-adrenoceptor. Neurochem Int 38: 317–322.
43. Tufek A, Tokgoz O, Aliosmanoglu I, Alabalik U, Evliyaoglu O, Ciftci T, et al. (2013). The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats. Int J Surg 11: 96–100.
44. Willigers HM, Prinzen FW, Roekaerts PM, de Lange S, Durieux ME (2003). Dexmedetomidine decreases perioperative myocardial lactate release in dogs. Anesth Analg 96: 657–664.
45. Xu H, Aibiki M, Seki K, Ogura S, Ogli K (1998). Effects of dexmedetomidine, an alpha2-adrenoceptor agonist, on renal sympathetic nerve activity, blood pressure, heart rate and central venous pressure in urethane-anesthetized rabbits. J Auton Nerv Syst 71: 48–54.